

Investor News

NeuroSearch to make a presentation at the 10th Annual Bear Stearns Healthcare Conference

NeuroSearch will make a presentation at the 10th Annual Bear Stearns Healthcare Conference to be held on 13 March 2008 in London.

NeuroSearch's presentation is scheduled for

Thursday 13 March 2008 at 9.30-10.45 local time

and will be held by CEO Flemming Pedersen.

A powerpoint version of the presentation will be available via www.neurosearch.com just after the presentation has been held at the conference.

Contact person:

Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications,
telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 12 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder/Parkinson's disease (Phase I), ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott, NSD-644 in pain a.o. (Phase I) in partnership with GSK and ACR343 in Parkinson's disease (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.